about
Cardiovascular Effects of the New Weight Loss Agents.2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart AssociPCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers.JCL roundtable: Risk evaluation and mitigation strategy.Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary interventionSystematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values.Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management.The recent national lipid association recommendations: how do they compare to other established dyslipidemia guidelines?Management of Hypogonadism in Cardiovascular Patients: What Are the Implications of Testosterone Therapy on Cardiovascular Morbidity?Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology.Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels.LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design.ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence aUse of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop.Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapeutics.Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry.Suboptimal risk factor control in patients undergoing elective coronary or peripheral percutaneous intervention.The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis.Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention.Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry.Laparoscopic gastric banding resolves the metabolic syndrome and improves lipid profile over five years in obese patients with body mass index 30-40 kg/m(2.).Genetic effects on efficacy of lipid-lowering drugs.What is sufficient drug therapy for lipoprotein elevations?Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice.ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence aUpdate on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trialUtility of Different Lipid Measures to Predict Coronary Heart Disease2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Associa2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery DiseaseLowering LDL-Cholesterol and CV Benefits: Is There a Limit to How Low LDL-C Needs to be for Optimal Health Benefits?Cardiovascular Risk Factor Control and Lifestyle Factors in Young to Middle-Aged Adults with Newly Diagnosed Obstructive Coronary Artery DiseaseLongitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry
P50
Q30248410-DB832C2B-32E6-4257-A692-29E1ED6E7230Q30586557-1D118472-01B2-4D05-BA8F-2D9CAD0C1CECQ33625574-955C35BE-9DE5-4025-A608-2A5D307D53C6Q34546659-FF5215D8-E1AF-4444-8077-87BFB8DE03EBQ35501523-4B1AD1BC-078C-4BF5-A221-1C987B3C38A1Q36412515-76C497A4-76D4-4683-92F7-19ACAC1F38CBQ37182703-D995141D-0EC6-4F1D-907A-E740A5AAE674Q37811998-54ED4459-D5C3-436B-B381-638753EB6B50Q38359106-B9412F15-6E25-4F15-B2E2-326D6714520BQ38822117-50DB02D8-6575-46C7-A836-A0FE8453D337Q38989499-936EFCEA-E7D1-437B-844C-11C0AC054767Q40213718-1F2A5D19-16EB-4571-A66D-2C4D6545ADA0Q40812371-1EB1457F-9E9A-4436-ABCC-63CA297A19B2Q41877686-16763576-6F9D-4B0B-9352-3E37782D20CAQ43592162-C4752297-C594-4590-A326-0C6967081102Q44041499-2787EB00-C98D-4EE5-A1AA-5128DA60BDF1Q44730223-41E455E8-BB0B-4BAA-BE25-24C5AB1D0124Q46947291-DC716244-E6EA-4217-A96A-33DB660A5EC1Q47610317-CAA7077A-B125-41FC-A860-B7CB4FFD13E6Q47669541-FDD1A207-2175-479A-8201-ECF7CFC9BF66Q47697188-FE8A4B86-08C1-42AD-A488-5BDA63689458Q48065009-E03048BE-60C8-4A2E-97A1-11EFE7E11A95Q49886391-1E05C7FF-A96F-402D-9257-7E0B3793E13DQ50163003-C5BE04B2-310B-4648-824E-4E2CE1315D94Q51638640-9877E170-7D50-470D-A0C0-0905504D2A5FQ51809161-D0A47695-3D76-4EAD-B02D-6800DE392CD0Q53110136-84CE1838-3377-4BA6-A06A-C89C50616227Q56971676-DE8BD79C-FC8F-43CB-ACAD-40E05B900152Q57393181-1619D269-0FB4-4967-B5A8-CFBDE636DBDFQ57630298-90F11AED-D72B-421D-AC79-B2A5EE3AE499Q57630301-AF16198A-D2F3-4A36-B0E9-329CC8DDE8BAQ89040695-70788278-7E56-43F2-8DB8-1286B041AD6AQ91952124-2736601D-B35F-413E-8BDF-59DFCD06EC65Q93124443-C9B1108A-4007-4E55-9E95-10B2705A782D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
James A Underberg
@ast
James A Underberg
@en
James A Underberg
@es
James A Underberg
@nl
James A Underberg
@sl
type
label
James A Underberg
@ast
James A Underberg
@en
James A Underberg
@es
James A Underberg
@nl
James A Underberg
@sl
altLabel
James Underberg
@en
prefLabel
James A Underberg
@ast
James A Underberg
@en
James A Underberg
@es
James A Underberg
@nl
James A Underberg
@sl
P106
P21
P31
P496
0000-0002-6615-8535